Literature DB >> 12956417

Exploring the role of 5' alternative splicing and of the 3'-untranslated region of cathepsin B mRNA.

Roman Zwicky1, Kathrin Müntener, Gabor Csucs, Mary B Goldring, Antonio Baici.   

Abstract

The cysteine peptidase cathepsin B is responsible for connective tissue breakdown in several diseases. The pathological expression of cathepsin B may depend on the structure of its mRNA. We investigated the translational efficiency of the cathepsin B mRNA untranslated regions (UTRs) using fusion constructs to green fluorescent protein (GFP) and luciferase. Transfection of fusion constructs with GFP and luciferase containing the full-length 5'-UTR, the variant lacking exon 2, and that lacking exons 2 and 3 into mammalian cells, resulted in modulation of the biosynthetic rate of cathepsin B in a cell-specific manner. Constructs missing these exons were biosynthetically more efficient than the full-length counterpart. Luciferase was cloned upstream of the 3'-UTR, downstream of the 5'-UTR, or sandwiched between the 5'- and the 3'-UTR. The UTRs of cathepsin B downregulated luciferase biosynthesis moderately when present individually, with the 3'-UTR being more efficient than the 5'-UTR, and downregulated it even more when present simultaneously. A truncated cathepsin B-GFP chimeric product derived from the 5'-UTR missing exons 2 and 3 induced cell death. The increased biosynthetic rate and abnormal trafficking of cathepsin B observed in pathologies such as cancer and osteoarthritis may depend on alternative splicing of pre-mRNA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12956417     DOI: 10.1515/BC.2003.113

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  8 in total

Review 1.  Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges.

Authors:  Klaudia Brix; Joseph McInnes; Alaa Al-Hashimi; Maren Rehders; Tripti Tamhane; Mads H Haugen
Journal:  Protoplasma       Date:  2014-11-16       Impact factor: 3.356

2.  Cathepsin B: Basis Sequence: Mouse.

Authors:  Dora Cavallo-Medved; Kamiar Moin; Bonnie Sloane
Journal:  AFCS Nat Mol Pages       Date:  2011-04-10

Review 3.  Cathepsin B: A sellsword of cancer progression.

Authors:  Olja Mijanović; Ana Branković; Alexander N Panin; Solomiia Savchuk; Peter Timashev; Ilya Ulasov; Maciej S Lesniak
Journal:  Cancer Lett       Date:  2019-02-20       Impact factor: 8.679

4.  Diversity in tissue expression, substrate binding, and SCF complex formation for a lectin family of ubiquitin ligases.

Authors:  Kevin A Glenn; Rick F Nelson; Hsiang M Wen; Adam J Mallinger; Henry L Paulson
Journal:  J Biol Chem       Date:  2008-01-18       Impact factor: 5.157

5.  A double-headed cathepsin B inhibitor devoid of warhead.

Authors:  Patricia Schenker; Pietro Alfarano; Peter Kolb; Amedeo Caflisch; Antonio Baici
Journal:  Protein Sci       Date:  2008-09-16       Impact factor: 6.725

6.  Complex splicing control of the human Thrombopoietin gene by intronic G runs.

Authors:  Roberto Marcucci; Francisco E Baralle; Maurizio Romano
Journal:  Nucleic Acids Res       Date:  2006-12-07       Impact factor: 16.971

Review 7.  Extralysosomal cathepsin B in central nervous system: Mechanisms and therapeutic implications.

Authors:  Junjun Ni; Fei Lan; Yan Xu; Hiroshi Nakanishi; Xue Li
Journal:  Brain Pathol       Date:  2022-04-12       Impact factor: 7.611

8.  Proteomic Analysis of Synovial Fibroblasts and Articular Chondrocytes Co-Cultures Reveals Valuable VIP-Modulated Inflammatory and Degradative Proteins in Osteoarthritis.

Authors:  Selene Pérez-García; Valentina Calamia; Tamara Hermida-Gómez; Irene Gutiérrez-Cañas; Mar Carrión; Raúl Villanueva-Romero; David Castro; Carmen Martínez; Yasmina Juarranz; Francisco J Blanco; Rosa P Gomariz
Journal:  Int J Mol Sci       Date:  2021-06-16       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.